Weekly News Wire | April 23, 2024

FDA Approves Otsuka & Click Therapeutics Rejoyn™ Prescription Digital Therapeutic For Adjunct Depression Treatment

On March 30, 2024, the Food and Drug Administration (FDA) granted marketing clearance to Otsuka America for its Rejoyn prescription digital therapeutic (PDT) developed with Click Therapeutics as an adjunct treatment for adults with major depressive disorder (MDD). Otsuka and Click plan to begin offering the app for download in the latter half of 2024. Rejoyn will be available for the iOS and Android operating systems. No price point has been announced.

The Rejoyn PDT is a six-week treatment program for use with clinical professional-managed outpatient treatment for MDD. The program includes emotional training exercises to enhance cognitive . . .

Want To Read More? Log In Or Become A Paid Member

Resource Available For Paid OPEN MINDS Circle Members Only

Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

About

Contact

Partnership

FDA Approves Otsuka & Click Therapeutics Rejoyn™ Prescription Digital Therapeutic For Adjunct Depression Treatment

Tagged As:

About

Contact

Partnership

Markets

Services

Customers

Publications

Markets

Topics

Executive Institutes

Professional Development Programs

Tools

Assessments

Tagged As: